Role of Endothelin in Microvascular Dysfunction Following PCI for Non-ST Elevation Myocardial Infarction
Myocardial Reperfusion Injury
Enrolment: 23 · Results not recorded
Loading the evidence…
Drug · Endothelin receptor ET-A antagonist (ANTAGONIST; direct interaction, disease efficacy true)
1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Myocardial Reperfusion Injury
Enrolment: 23 · Results not recorded
Prehypertension · Hypertension
Enrolment: 42 · Results not recorded
ST-Elevation Myocardial Infarction
Enrolment: 57 · Results not recorded
Pulmonary Hypertension
Enrolment: 38 · Results not recorded
Chronic Obstructive Pulmonary Disease · Pulmonary Artery Hypertension · Heart Failure · Hypertension
Enrolment: 420 · Results not recorded
Heart Failure
Enrolment: 30 · Results not recorded
Chronic Kidney Disease · Proteinuria
Enrolment: 22 · Results not recorded
Cardiovascular Diseases · Cardiovascular Risk Factor · Vasoconstriction
Enrolment: 19 · Results not recorded
Healthy Conditions
Enrolment: 8 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Cisplatin-induced acute renal failure (single 6 mg/kg intraperitoneal dose)
BQ-123 ameliorated the structural, functional and biochemical injury caused by cisplatin, mainly through restoration of superoxide dismutase activity along with improvements in nitric oxide, TNF-alpha and caspase-3, indicating that ETA rather than ETB receptors mediate cisplatin nephrotoxicity.
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.